Trimetrexate (glucuronate)

Trimetrexate glucuronate (NSC 352122) is a folic acid antagonist. Trimetrexate glucuronate affects DNA and RNA synthesis by inhibiting dihydrofolate reductase and preventing the synthesis of purine nucleotides and thymidylate. Trimetrexate glucuronate has potential antitumour activity and can also be used to inhibit Pneumocystis carinii pneumonia[1][2].

Product Specifications

CAS Number

[82952-64-5]

Product Name Alternative

CI-898 (glucuronate)

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H335

Target

Antifolate; Bacterial

Type

Reference compound

Related Pathways

Anti-infection; Cell Cycle/DNA Damage

Applications

Cancer-programmed cell death

Field of Research

Cancer; Infection

Assay Protocol

https://www.medchemexpress.com/trimetrexate-glucuronate.html

Purity

98.09

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C[C@@H]([C@H]([C@@H]([C@@H](C(O)=O)O)O)O)O.NC1=NC(N)=C2C(C)=C(CNC3=CC(OC)=C(OC)C(OC)=C3)C=CC2=N1

Molecular Formula

C25H33N5O10

Molecular Weight

563.56

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

References & Citations

[1]R C Jackson, et al. Biochemical pharmacology of the lipophilic antifolate, trimetrexate. Adv Enzyme Regul. 1984;22:187-206.|[2]P J Harris, et al. Trimetrexate glucuronate associated with anti-Kaposi sarcoma effect. AIDS Patient Care STDS. 1996 Oct;10 (5) :280-1.